A5050595153- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer therapeutics and mechanisms
- Acute Lymphoblastic Leukemia research
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Immunotherapy and Immune Responses
- Medical Imaging and Pathology Studies
- Hepatitis C virus research
- Methemoglobinemia and Tumor Lysis Syndrome
- Cancer Treatment and Pharmacology
- Inflammatory Biomarkers in Disease Prognosis
- Liver Disease Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Hepatitis B Virus Studies
Guangdong Academy of Medical Sciences
2018-2025
Southern Medical University
2022-2025
Guangdong Provincial People's Hospital
2019-2025
South China University of Technology
2019-2024
Nanfang Hospital
2016-2022
Cancer Institute (WIA)
2022
Guangdong General Hospital
2018
Zhujiang Hospital
2016
Backgrounds Immunotherapy is less effective in patients with epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC). Lower programmed cell death-ligand 1 (PD-L1) expression and tumor mutation burden (TMB) are reported to be the underlying mechanism. Being another important affect efficacy of immunotherapy, microenvironment (TME) characteristics this subgroup NSCLC not comprehensively understood up date. Hence, we initiated study describe specific TME EGFR-mutant...
Background The liver is a frequent site of metastases and (LM) correlate with diminished immunotherapy efficacy in non-small cell lung cancer (NSCLC). This study aimed to analyze whether tumor response differs between pulmonary lesions (PL) LM NSCLC explore potential mechanisms through multiomics analysis. Methods observational longitudinal clinical cohort included patients receiving was conducted evaluate organ-specific PL LM. We collected paired samples the difference using whole-exome...
Background EGFR‐tyrosine kinase inhibitors play an important role in the treatment of advanced non‐small cell lung cancer (NSCLC). EGFR mutations NSCLC occur approximately 35% Asian patients and 60% with adenocarcinoma. However, frequency type early‐stage adenocarcinoma remain unclear. Methods We retrospectively collected data on diagnosed tested for mutation. Early stage was defined as pathological IA–IIIA after radical surgery, clinical IIIB without opportunity curative or IV according to...
Background Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of ERBB2 have been extensively reported in non‐small cell lung cancer (NSCLC). Due to the increased accessibility next‐generation sequencing, more within non‐TKD can be detected clinical practice. Nevertheless, significance remains unknown. Hence, this study was designed comprehensively outline landscape characteristics NSCLC. Methods A total 1934 patients with NSCLC from cBioPortal were included...
The epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) has a unique "cold" immune profile. DNA damage repair (DDR) genes are closely related to tumorigenesis and the effectiveness of immunotherapy in many tumors. However, role mechanism DDR genesis progression EGFRm NSCLC remain unclear. This study included 101 samples from Cancer Genome Atlas (TCGA) dataset GSE31210 (external set) GEO database. Cluster analysis was used identify different subtypes based on...
Response to immune checkpoint inhibitors (ICIs) is affected by multiple factors. This study aimed explore whether sites of metastasis are associated with clinical outcomes ICIs in advanced non-small-cell lung cancer (NSCLC) patients.The data NSCLC patients high programmed death-ligand 1 expression and good performance status receiving first-line monotherapy from Guangdong Provincial People's Hospital between May 2019 July 2020 were retrospectively analyzed. Metastatic included liver, bone,...
Metabolism reprogramming within the tumor microenvironment (TME) can have a profound impact on immune cells. Identifying association between metabolic phenotypes and cells in lung adenocarcinoma (LUAD) may reveal mechanisms of resistance to checkpoint inhibitors (ICIs). Metabolic were classified by expression genes. Somatic mutations transcriptomic features compared across different phenotypes. The phenotype LUAD is predominantly determined reductase-oxidative activity divided into two...
Central nervous system (CNS) metastases is inevitable for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 a novel EGFR-TKI with impressive CNS penetration.We initiated phase 2, multi-center, umbrella trial (CTONG1702, NCT03574402). The eighth arm assessed the efficacy and safety of in untreated EGFR-mutated NSCLC metastases. primary objective was response rate (ORR). Simon's minimax two-stage design used to calculate sample size. Dose optimal...
EGFR C797X (C797S or C797G) mutation is the most frequent on-target mechanism of resistance to osimertinib. The hypothesis that allelic context C797X/T790M has implications for treatment on basis sporadic reports and needs validation with larger cohorts.
Background The lung is one of the most common target organs for malignant tumor metastasis. existence metastasis may have a decisive effect on choice treatment regimen. Minute pulmonary meningothelial‐like nodules (MPMNs) usually present as ground‐glass opacity or solid nodules, mimicking imaging findings nodules. This study summarizes clinical, radiological, and pathological features MPMNs to distinguish them from Methods Guangdong Lung Cancer Institute Pathology Information System was...
Epidermal growth factor receptor (EGFR) exon 20 insertion (EGFR ex20ins) is a common mutation in non-small cell lung cancer (NSCLC). Patients with EGFR ex20ins generally respond poor to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). are often co-occurring amplification. However, the impact of amplification on survival patients mutations has not been determined.This an observational longitudinal cohort study. A prospectively managed database included consecutive treatment-naïve adult advanced...
BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear.From October 2016 May 2020, with advanced NSCLC for whom next-generation sequencing detected mutations both retrospectively included. From June 2020 January 2021, who acquired the V600E mutation after progression on osimertinib prospectively enrolled explore efficacy safety plus BARF...
Rearranged during transfection (RET) fusions are important genetic drivers in non-small cell lung cancer (NSCLC). Selective RET inhibitors setting a new paradigm RET-driven NSCLC. However, the real-world treatment patterns, outcomes and toxicity remain largely unknown.Data from fusion-positive NSCLC patients treated our centre were retrospectively analysed. Of them, diagnosed before after August 2018 included analysis of patterns; received selective eligible for adverse events (AEs).Patients...
Background: Non-small-cell lung cancer (NSCLC) had poor prognosis in patients with central nervous system (CNS) metastases. Approved epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has limited ability to cross the blood–brain barrier. AZD3759 is a novel EGFR-TKI an impressive CNS penetration, but first-line data unknown and dose selection based on sample size. Methods: We initiated phase 2, multi-center, umbrella trial (CTONG1702, NCT03574402). In 8th arm, efficacy...
e21021 Background: BRAF variants were reported resistant mechanisms to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC). However, concomitant somatic variations other than and efficacy of subsequent treatment remained unclear. Methods: From October 2016 May 2020, advanced NSCLC patients who underwent next-generation sequencing detected with co-mutation EGFR activating mutations are retrospectively included. Since June...
Background: Targeting BCL-2 family proteins is a well-recognized therapeutic approach. Globally approved inhibitor venetoclax has shown efficacies in certain hematologic malignancies (HMs) but requires weekly ramp-up to the target dose mitigate risk of tumor lysis syndrome (TLS). LP-108 novel, highly potent, orally bioavailable, and selective that promising preclinical antitumor activity various HMs. Aims: To present preliminary results from an ongoing phase 1 study under daily patients with...